TyVECO: Surveillance Protocol
Launched by INTERNATIONAL VACCINE INSTITUTE · Sep 28, 2022
Trial Information
Current as of June 04, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- At health center:
- • 1. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with objective fever of at least 38.0°C tympanic or 37.5 °C axillary OR
- • 2. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with reported fever ≥3 consecutive days within 7 days of presentation
- At Hospital:
- • 1. Suspicion of intestinal perforation/peritonitis due to typhoid fever requiring surgery for patients living in and outside the catchment area (even in the absence of laboratory confirmation) OR
- • 2. Patients living in the catchment area of the hospital with invasive salmonellosis confirmed through blood-culture surveillance embedded in routine patient cares
- Exclusion Criteria:
- • Individuals who do not provide informed consent
About International Vaccine Institute
The International Vaccine Institute (IVI) is a non-profit organization dedicated to advancing global health through the development and delivery of innovative vaccines. Established in 1997 and headquartered in Seoul, South Korea, IVI collaborates with governments, academic institutions, and industry partners to conduct research and clinical trials aimed at preventing infectious diseases prevalent in low- and middle-income countries. By leveraging its expertise in vaccine development, IVI strives to enhance vaccine accessibility and affordability, ultimately contributing to the reduction of morbidity and mortality associated with vaccine-preventable diseases worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Kisantu, Bas Congo, Congo, The Democratic Republic Of The
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials